Literature DB >> 32418592

Barriers and Solutions for Prescribing Obesity Pharmacotherapy.

Ken Fujioka1, Samantha R Harris2.   

Abstract

There are many valid reasons why health care providers are reluctant to use pharmacotherapy for weight management: the negative track record of weight loss medications has led to numerous safety concerns, and there is lack of formal training in obesity medicine and a general discomfort with using these medications. New medications have improved safety profiles, and their mechanisms are based on recent discoveries of how humans regulate weight. This, combined with a change in American health coverage, has slowly increased the use weight loss medication. This article examines the barriers and changes that are increasing the use of anti-obesity medications.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Barriers; Obesity; Pharmacotherapy; Reimbursement; Weight loss

Mesh:

Substances:

Year:  2020        PMID: 32418592     DOI: 10.1016/j.ecl.2020.02.007

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  5 in total

1.  Perceptions of obesity pharmacotherapy by nurse practitioners.

Authors:  Katelyn Bottcher; Ariana M Chao
Journal:  J Am Assoc Nurse Pract       Date:  2021-12-01       Impact factor: 1.165

2.  Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.

Authors:  Tingxi Wu; Yang Zhang; Yanfeng Shi; Kefu Yu; Mei Zhao; Shangyi Liu; Zhigang Zhao
Journal:  Clin Drug Investig       Date:  2022-09-30       Impact factor: 3.580

3.  Long-term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study.

Authors:  Beverly G Tchang; Mohini Aras; Alan Wu; Louis J Aronne; Alpana P Shukla
Journal:  Obes Sci Pract       Date:  2021-12-02

Review 4.  Acupuncture Therapies for Individuals with Overweight or Obesity: An Overview of Systematic Reviews.

Authors:  Jiaxin Chen; Johannah L Shergis; Xinfeng Guo; Anthony Lin Zhang; Hanlin Wang; Chuanjian Lu; Charlie C Xue; Changcai Xie
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-30       Impact factor: 3.249

5.  Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.

Authors:  Yu Zhou; Mingyu Chen; Libin Liu; Zhou Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2022-01-13       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.